Diphtheria Completed Phase 4 Trials for Poliovirus type 2 antigen (formaldehyde inactivated) (DB10796)

Also known as: Corynebacterium diphtheriae infection / Infection due to Corynebacterium diphtheriae (disorder) / Diphtheria caused by Corynebacterium diphtheriae (disorder) / Diphtheria, unspecified

IndicationStatusPhase
DBCOND0000394 (Diphtheria)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04535037A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and ToddlersPrevention
NCT02853929Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryPrevention
NCT02422264Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryPrevention
NCT01659996Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgePrevention
NCT01491087Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in ChinaPrevention
NCT01437423Regulatory Post-Marketing Surveillance Study for TETRAXIM™Prevention
NCT01031303Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of AgePrevention
NCT00635128Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio VaccinePrevention
NCT00611559Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old ChildrenPrevention
NCT00255021Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandPrevention
NCT00254917Assessment of the Immunogenicity and Safety of PENTAXIM™ in PhilippinesPrevention